Archive | Biopharmaceuticals

Mid-Cap Biotechs Lead the Market: Pre-ASCO Scoreboard…Updates 6/4/18

http://crug-glas.co.uk/the-area/britains-smallest-city/ 6/4/18…after close Update-2…IBB down 0.65%, XBI down 0.22%.  Momentum Waning Big Winners Today : BLUE, FMI, GHDX, IMMU, MRK It would appear that biotech stocks need to be bought prior to ASCO as has been then trend in the past i.e sell before the news. However there will be some clear cut winners after the Meeting. […]

Continue Reading 0

Financial and Political Crisis in Italy Disrupts Biotech Stock Momentum…Updates with rally today 5/30

http://antiquewarehousemall.com/2013/12/van-briggle-maiden-bowl/ Updates 5/30 Pre-ASCO Rally: XBI regains momentum to $94 level. IBB breaks through SMA 200 level to $108+. Many mid-caps from our watch list soaring-CRSP*, FMI, FOLD, LGND, LOXO, NKTR, SGEN, SRPT etc. *Note CRSP got whacked after hours down 13 points! The FDA has put the clinical trial for sickle cell treatment on hold. […]

Continue Reading 0

Biotech Mid-Caps: The Momentum Trade is Back FMI, LOXO,XBI etc

http://sukeyjumpmusic.com/heidi Biotech Mid-Caps- Momentum Trade is Back ASCO Abstracts Provide Clinical Updates But as of 2 P EDT Stocks Are Being Hit By Profit Taking XBI at $92.39 Biotech mid-caps had a good week ending 5/18 as tracked by the top performing XBI which was up 2%  and over 10% in 2018 YTD. The large cap […]

Continue Reading 0

Biotechs Soar After Big Trump Drug Price Speech- Mid-Caps Should Outperform…Updates

Update: 5/17…Mini-Rally Continues With Help From ASCO Abstracts XBI hits $93.78 above April highs, up 5.32% over 5 days, 10.5% YTD. IBB at April highs at $107.59, up 3.62% over 5 days, up 0.77% YTD Many Mid-Caps are hot: BLUE, CRSP, EXEL, FOLD, LGND, LOXO. See our list below. Gene editing stocks move up: CLLS, […]

Continue Reading 0

Biotech Stocks Underperform Market: CELG, EXEL, PBYI, XBI…Updates 5/11…Big Rally on Drug Pricing Speech

Trump Speech on Plan for Lower Drug Prices 5/11 After close. Biotech and healthcare stocks were broadly higher. Key words by HHS Secretary were “complex” and “will take time”; more updates tomorrow. General objectives appear to be to lower list prices and squeeze middlemen like PBMs, offer Part-D type discount with Part-B drugs and promote […]

Continue Reading 0

Biotechs Survive 2018 Bottom and Catch a Rally Today…Update 5/9

Update 5/8/18 Biotechs Rally Above Near Term Support (XBI) at SMA 20 XBI up 1.96% to $89.80. IBB up 1.35% to $103.79; twelve month quadruple bottom is near $100 level. Small and mid caps should outperform because of news and M&A potential. Large caps: Celgene (CELG) down 20.66% over 12 month lows at $82.80. Large caps: Abbvie(ABBV) […]

Continue Reading 0

Biotechs Bounce From Support Levels Despite Mixed Earnings Reports…Update 5/3- Testing 2018 Lows

5/3 Testing February bottom and 200 MA of ~$100 on IBB and ~$85 on XBI. Red screen day. 2PM EDT Dow near flat line. Need to look for major gap up. Another potential negative on the horizon: “Bold Action on Drug Pricing” by Sect’y HHS. 5/2  Biotech Stocks Are About To Test 2018 Lows: It […]

Continue Reading 0

2018 Biotech Sector Watch on Earnings #2: ABBV, ALXN, BMY…Updates VRTX

Update 4/30… Vertex Pharmaceuticals (VRTX) Beat Consensus by 4% Financial Results: CF Revenues rose 33% Q’18 o Q’17 from $481M to $638M; GAAP net income down 15% ,$210M from $241M. Two Phase 3  triple combination clinical development programs are underway : VX-559 and VX-441 best for 2020 launch as well as pain and sickle cell R&D.  […]

Continue Reading 0

2018 Biotech Sector Watch on Earnings #1: AMGN,BIIB…Updates

Update 4/25: Investors May See Value in Large Cap Biotech Amgen (AMGN) up 1.68%. Biogen (BIIB) holds Tuesday lows of $262 Up 2.78% today. IBB flat at $103.26 More earnings tomorrow but it is all about technicals holding the recent bottom. ========== Biotech Sector Watch on 2018 Earnings Interest Rates at 3% Rising Too Fast? […]

Continue Reading 0

Biotech and Pharma Stocks Await Q1 Earnings But Gene Editing Stocks Sell-Off

Speculative Biotech Stocks Sell-Off in Profit Taking: Gene Editing Biotech stocks held current levels but small caps and speculative stocks sold off with the XBI down 1%. Most large caps were in the green with an upgrade from Goldman Sachs helping Merck (MRK) up 2.4% with a bullish story on Keytruda. Amgen (AMGN) offers good […]

Continue Reading 0